Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tulchinsky

Showing results (361-370 of 378) with videos related to

Pageof 38
Sort By:
Endocrine|March 27, 2021
Assessing potential impact of 2015 American Thyroid Association guidelines on community standard practice for I-131 treatment of low-risk differentiated thyroid cancer: case study of JordanMalik E Juweid, Nidal J Rabadi, Mark Tulchinsky, et al.
Cell Death & Disease|September 24, 2019
Protein kinase C inhibitors override ZEB1-induced chemoresistance in HCCRahul Sreekumar, Muhammad Emaduddin, Hajir Al-Saihati, et al.
Journal of the American College of Radiology : JACR|November 6, 2012
ACR Appropriateness Criteria pretreatment staging of colorectal cancerCatherine Dewhurst, Max P Rosen, Michael A Blake, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 27, 2009
SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancerA Emre Sayan, Thomas R Griffiths, Raj Pal, et al.
Molecular Oncology|May 1, 2021
The ZEB2-dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancerRahul Sreekumar, Hajir Al-Saihati, Muhammad Emaduddin, et al.
Science Signaling|August 20, 2015
The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanomaRachel Ramsdale, Robert N Jorissen, Frederic Z Li, et al.
American Journal of Clinical Oncology|July 22, 2025
ACR-ACNM-ARS-SNMMI-SPR Practice Parameter for Treatment of Benign and Malignant Thyroid Disease With I-131 Sodium IodideAndrew T Trout, Thomas P Boike, Anca M Avram, et al.
Journal of the American College of Radiology : JACR|November 5, 2011
ACR Appropriateness Criteria® right lower quadrant pain--suspected appendicitisMax P Rosen, Alexander Ding, Michael A Blake, et al.
Iscience|December 1, 2025
Fosl1 is a transcriptional effector of <i>BRAF</i> <sup>V600E</sup>-driven intestinal tumorigenesisZakia Alam, Rebecca Nightingale, Analia Lesmana, et al.
International Journal of Public Health|March 14, 2025
Public Health Workforce Professional Development Analysis: A Human-Systems Integration for Healthy CommunitiesBashkin Osnat, Baron-Epel Orna, Bochenek Tomasz, et al.
Pageof 38

Showing results (361-370 of 378) with videos related to

Sort By:
Pageof 38
Endocrine|March 27, 2021
Assessing potential impact of 2015 American Thyroid Association guidelines on community standard practice for I-131 treatment of low-risk differentiated thyroid cancer: case study of JordanMalik E Juweid, Nidal J Rabadi, Mark Tulchinsky, et al.
Cell Death & Disease|September 24, 2019
Protein kinase C inhibitors override ZEB1-induced chemoresistance in HCCRahul Sreekumar, Muhammad Emaduddin, Hajir Al-Saihati, et al.
Journal of the American College of Radiology : JACR|November 6, 2012
ACR Appropriateness Criteria pretreatment staging of colorectal cancerCatherine Dewhurst, Max P Rosen, Michael A Blake, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 27, 2009
SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancerA Emre Sayan, Thomas R Griffiths, Raj Pal, et al.
Molecular Oncology|May 1, 2021
The ZEB2-dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancerRahul Sreekumar, Hajir Al-Saihati, Muhammad Emaduddin, et al.
Science Signaling|August 20, 2015
The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanomaRachel Ramsdale, Robert N Jorissen, Frederic Z Li, et al.
American Journal of Clinical Oncology|July 22, 2025
ACR-ACNM-ARS-SNMMI-SPR Practice Parameter for Treatment of Benign and Malignant Thyroid Disease With I-131 Sodium IodideAndrew T Trout, Thomas P Boike, Anca M Avram, et al.
Journal of the American College of Radiology : JACR|November 5, 2011
ACR Appropriateness Criteria® right lower quadrant pain--suspected appendicitisMax P Rosen, Alexander Ding, Michael A Blake, et al.
Iscience|December 1, 2025
Fosl1 is a transcriptional effector of <i>BRAF</i> <sup>V600E</sup>-driven intestinal tumorigenesisZakia Alam, Rebecca Nightingale, Analia Lesmana, et al.
International Journal of Public Health|March 14, 2025
Public Health Workforce Professional Development Analysis: A Human-Systems Integration for Healthy CommunitiesBashkin Osnat, Baron-Epel Orna, Bochenek Tomasz, et al.
Pageof 38